A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
A Phase III Study of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects with Poor Efficacy of MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
Sponsor: RemeGen Co., Ltd.
Listed as NCT03016013, this PHASE3 trial focuses on Moderate and Severe RheumatoId Arthritis and remains completed. Sponsored by RemeGen Co., Ltd., it has been updated 12 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Oct 2021 — Feb 2022 [monthly]
Recruiting PHASE3
-
May 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2018 — Apr 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- RemeGen Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .